ALDXAldeyra Therapeutics, Inc.

Nasdaq aldeyra.com


$ 3.27 $ 0.19 (6.17 %)    

Thursday, 28-Mar-2024 15:59:55 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 3.27
$ 3.18
$ 0.00 x 0
$ 0.00 x 0
$ 3.18 - $ 3.47
$ 1.42 - $ 11.97
859,171
na
192.74M
$ 1.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-07-2024 12-31-2023 10-K
2 11-03-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-05-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 10-28-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-11-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-08-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 03-29-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-30-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-10-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 03-30-2016 12-31-2015 10-K
34 11-13-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-23-2015 12-31-2014 10-K
38 11-12-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 06-11-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aldeyra-therapeutics-reports-advancement-of-rasp-platform-in-systemic-and-retinal-inflammatory-diseases

Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, ...

Core News & Articles

As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to Aldeyra at any tim...

 positive-news-for-skin-health-aldeyra-therapeutics-adx-629-achieves-key-milestones-in-atopic-dermatitis-study

Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational R...

Core News & Articles

CGEN: 240% | Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Ph...

 aldeyra-therapeutics-schedules-conference-call-and-webcast-on-tuesday-december-19-2023-at-800-am-to-announce-top-line-results-from-phase-2-clinical-trial-of-adx-629-in-patients-with-atopic-dermatitis

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, Decem...

 fda-rejects-aldeyra-therapeutics-dry-eye-disease-candidate-asks-for-additional-study

The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reprox...

 why-extreme-networks-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers

 whats-going-on-with-aldeyra-therapeutics-stock

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares are trading higher Wednesday after the company announced that it entered into ...

Core News & Articles

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative th...

Core News & Articles

CLLS: 185% | Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca ALDX: 38% | Aldeyra Therap...

 citigroup-maintains-buy-on-aldeyra-therapeutics-lowers-price-target-to-8

Citigroup analyst Yigal Nochomovitz maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and lowers the price target from...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION